Child PsychiatryOdysee3NCT07068945
Study of the Transition From Child Psychiatry to Adult Psychiatry in Nice Within a Population of 17-year-old Adolescents
An observational study of Child Psychiatry, run by Fondation Lenval at 1 site in France.
Trial summary
Transitional psychiatry addresses the complex process through which individuals move from adolescence to adulthood, both in terms of developmental stage and mental healthcare systems. Read more about this study
- Who is it for?
- Ages 17 to 17 years
- Conditions the study is for
- Child Psychiatry
- What is being tested?
- Group of 17-year-old patients living in Nice and receiving psychiatric care
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 7 Apr 2026to 15 Sep 2028
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 17 to 17 years
- All sexes
- No healthy volunteers
- Child
Study population: Group of 17-year-old patients living in Nice and receiving psychiatric care
Who may be able to join
- Participants must meet all of the following criteria:
- Age ≥17 and <18 years at inclusion.
- Receiving care (outpatient, inpatient, or emergency) within the Child and Adolescent Psychiatry Department at Lenval University Children's Hospital.
- Presence of a psychiatric disorder according to DSM-5 criteria, irrespective of diagnostic category.
- Considered to be in a potential transition situation to adult mental health services within the following 12 months.
- Living in the municipality of Nice (postal codes 06000, 06100, 06200, 06300).
- Able to provide written informed consent, together with at least one parent or legal guardian.
Who cannot join
- Participants meeting any of the following criteria will be excluded:
- Insufficient command of French preventing comprehension of study information or completion of questionnaires.
- Cognitive or sensory impairments (e.g. moderate-to-severe intellectual disability, major visual impairment, severe reading difficulties) preventing valid completion of assessments.
- Legal incapacity (e.g. guardianship) preventing independent consent.
- Acute or unstable clinical condition requiring urgent or intensive care incompatible with research participation (e.g. severe psychiatric decompensation, immediate suicidal crisis).
- Refusal to participate by the adolescent or the parent(s)/legal representative(s).
- Any situation judged by the investigator as incompatible with one-year follow-up (e.g. imminent transfer to another region).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Louis-Emilie Dumas, Child and adolescent psychiatr contact
France1 site, 1 recruiting
- Recruiting
Fondation Lenval Hôpitaux pédiatrique Nice CHU Lenval
Nice, 06200
Louise -Emilie Dumas, MD, +33(0)4 92 03 03 26, louise-emilie.dumas@hpu.lenval.com
Louise- Emilie Dumas, MD
About this study
Transitional psychiatry addresses the complex process through which individuals move from adolescence to adulthood, both in terms of developmental stage and mental healthcare systems. This transition includes the shift from pediatric to adult psychiatric services, as well as the evolution from vague or subclinical symptoms to established psychiatric disorders that may become chronic without early intervention.
Psychiatric disorders often emerge early in life: approximately 50% before age 15 and 75% before age 25. Early detection and intervention are therefore crucial to improving long-term mental health outcomes, functional independence, and social integration. However, current healthcare systems frequently fail to meet the needs of adolescents and young adults during this critical transition phase. Organizational discontinuities and clinical complexity lead to several risks:
Read more
- Difficulties in accessing appropriate psychiatric care for adolescents presenting with emerging symptoms,
- High rates of service disengagement for patients already receiving pediatric mental health care who do not successfully transition to adult services.
Studies have shown that nearly half (48%) of young people drop out of psychiatric follow-up for at least three months after reaching adulthood. This interruption increases the likelihood of relapse and involuntary psychiatric admissions. Despite numerous publications over the past decade emphasizing the need for dedicated transitional care models, services remain fragmented in many systems.
One of the largest recent studies in this area, the European MILESTONE longitudinal study, followed 763 patients (mean age 17.5) over two years in eight countries. It found that 11% of participants discontinued care entirely, 41% experienced discontinuity, and only 21% successfully transitioned to adult psychiatry. Continued care was more likely among patients with severe psychiatric disorders who had already accepted treatment. In contrast, those with mood disorders or poorly defined symptoms-despite being at high risk-were less likely to receive ongoing support.
Transitional psychiatry therefore aims to establish integrated practices and systems that ensure the continuity of mental healthcare for youth aged approximately 16 to 25. The main objectives of such services are to:
- Prevent care disruptions at the age of majority,
- Maintain appropriate and developmentally sensitive treatment for young adults,
- Promote patient autonomy in managing their care,
- Ensure coordination and collaboration between child/adolescent and adult psychiatric teams.
Despite growing recognition of these needs, no consensus exists in the literature regarding a fixed duration that defines a true care discontinuity, and practices vary significantly between regions and systems.
In this context, the Odyssée 3 project was launched in Nice, France, as a prospective epidemiological study focusing specifically on the real-life transition from child and adolescent psychiatry to adult psychiatry. The study targets a cohort of 17-year-olds who are currently receiving mental health care and will soon face the shift to adult services.
The project is part of the CNR Santé Mentale territorial initiative, supported by the Regional Health Agency (ARS 06). It is co-led by the University Department of Child and Adolescent Psychiatry (SUPEA) at Lenval Pediatric University Hospital and the Department of Psychiatry at the Nice University Hospital (CHU de Nice).
Odyssey 3 has three primary goals:
- To assess the care pathways and clinical outcomes of adolescents undergoing transition to adult psychiatry;
- To identify patient profiles, trajectories, and risk factors associated with successful or failed care continuity;
- To generate data that will inform the creation of a dedicated transitional psychiatry team and pathway in the Nice area.
Ultimately, this study aims to strengthen the healthcare system's ability to detect early warning signs, intervene proactively in emerging psychiatric conditions, and ensure that adolescents already engaged in care do not experience service discontinuities. Its findings will serve as a foundation for building a specialized, coordinated, and sustainable transitional psychiatry structure in Nice, aligned with best practices and international recommendations.
- Conditions
- Child Psychiatry
- Being tested
- Group of 17-year-old patients living in Nice and receiving psychiatric care
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group of 17-year-old patients living in Nice and receiving psychiatric careBehavioural
Prospective study aiming to determine the annual prevalence of 17-year-old patients living in Nice who attend hospital-based child and adolescent psychiatry services. Secondary objectives include: estimating prevalence among under-18 psychiatric patients; describing clinical and sociodemographic profiles (sample of 100 patients); mapping 1-year care trajectories; evaluating clinical outcomes; assessing transition preparedness (to adult psychiatry); and identifying factors associated with psychiatric care continuity at 12 months.
| Study group | Role | What they receive |
|---|---|---|
| Group of 17-year-old patients living in Nice and receiving psychiatric care | Group of 17-year-old patients living in Nice and receiving psychiatric care Receives: Behavioral: Group of 17-year-old patients living in Nice and receiving psychiatric care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Annual prevalence of 17-year-old patients living in Nice who consulted hospital-based child and adolescent psychiatry services, calculated against the total number of 17-year-olds in the general population of Nice.
Annual prevalence is defined as the number of 17-year-old patients living in the city of Nice who consult hospital-based child and adolescent psychiatry services within a one-year period, divided by the total number of 17-year-olds in the general population of Nice. The calculation was performed using data from INSEE (French National Institute of Statistics and Economic Studies).
Measured: one year
Secondary outcomes (9)
Annual Prevalence of 17-Year-Old Adolescents Consulting Child and Adolescent Psychiatric Services in Nice
The annual prevalence is defined as the proportion of 17-year-old adolescents living in the municipality of Nice who consulted the child and adolescent psychiatric hospital services at HPU Lenval during a given year, among all minors (<18 years) living in Nice who had at least one psychiatric consultation at HPU Lenval during the same year.
Measured: One year following the first psychiatric consultation during the study period.
Baseline Description of Patient Profiles in a Child and Adolescent Psychiatric Population
This outcome corresponds to a detailed baseline characterization of the study population based on a sample of 100 patients specifically included in the study. Predefined socio-demographic and medical characteristics were collected and analyzed.
Measured: Baseline
One-Year Psychiatric Care Trajectories in Adolescents
The one-year care trajectory of patients will be assessed according to changes in their psychiatric management during follow-up. At 12 months (M12), patients will be classified into the following categories: continuation of care in child and adolescent psychiatry, transition to adult psychiatry services, discontinuity or interruption/resumption of care, planned termination of care agreed upon by the patient and medical team, or lost to follow-up.
Measured: 12 months after study inclusion
Clinical Evolution
Clinical evolution will be assessed using the MINI-S questionnaire administered at baseline (M0), 6 months (M6), and 12 months (M12). Descriptive analyses of questionnaire responses will be performed at each study time point. Only items related to the participant's current clinical state will be considered.
Measured: Baseline (M0), 6 months (M6), and 12 months (M12).
Transition Readiness and Appropriateness Measure (TRAM)
Transition readiness and appropriateness will be assessed using the Transition Readiness and Appropriateness Measure (TRAM), a validated multidimensional questionnaire developed within the MILESTONE project. The Young Person version will be administered. The TRAM evaluates whether a young person is appropriately prepared for transition from child and adolescent mental health services by assessing symptom burden, overall illness severity, functional disruption, risk factors, factors affecting symptoms, barriers to functioning, and transition readiness. Multiple subscale scores will be calculated according to the TRAM scoring manual, with exploratory analyses focusing on the most clinically relevant outcomes.
Measured: Baseline (M0) and 6 months (M6).
Continuity of Psychiatric Care at 12 Months
Continuity of psychiatric care will be assessed at 12 months (M12). Continuity will be considered achieved if the participant has a defined psychiatric care plan at 12 months or has achieved clinical recovery and no longer requires psychiatric follow-up. The outcome will be recorded as a binary variable (Yes/No) based on the investigator's assessment.
Measured: 12 months (M12).
WHOQOL-BREF Quality of Life Score
Quality of life will be assessed using the WHOQOL-BREF questionnaire administered at baseline (M0), 6 months (M6), and 12 months (M12). Changes in questionnaire scores over time will be described
Measured: Baseline (M0), 6 months (M6), and 12 months (M12).
Psychosocial Functioning (Health of the Nation Outcome Scales for Children and Adolescents [HoNOSCA] Total Score
Psychosocial functioning will be assessed using the Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA) questionnaire, administered at baseline (M0), 6 months (M6), and 12 months (M12). The HoNOSCA consists of 15 items, of which 13 clinical items contribute to the total score, each rated from 0 (no problem) to 4 (severe or very severe problem). The total score ranges from 0 to 52, with higher scores indicating greater psychosocial difficulties and poorer psychosocial functioning. Changes in the total HoNOSCA score over time will be described.
Measured: Baseline (M0), 6 months (M6), and 12 months (M12).
Outcome of Transition to Adult Psychiatric Care (Transition Related Outcome Measure [TROM] Total Score)
Transition outcomes will be assessed using the Transition Related Outcome Measure (TROM), a validated multidimensional questionnaire developed within the MILESTONE project. The Young Person version will be administered at the 12-month follow-up. The TROM evaluates the quality and outcomes of the transition process by assessing changes in symptoms, overall illness severity, functional disruption, risk factors, activities facilitating transition, quality of care and other transition-related outcomes. Multiple subscale scores will be calculated according to the TROM scoring manual, with exploratory analyses focusing on the most clinically relevant outcomes.
Measured: 12 months (M12).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2025
- Study start7 Apr 2026
- Primary completion15 Sep 2028 (estimated)
- Study completion15 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Child PsychiatryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Fondation Lenval
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07068945
- Sponsor's protocol ID
- 25-HPNCL-04 Odysee3
- Acronym
- Odysee3
- Status last verified
- Aug 2026
- First submitted
- 7 Jul 2025
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified individual participant data collected during the study will be made available upon reasonable request following publication of the primary results, subject to applicable ethical and legal regulations.
Publications
Dumas LE, Marchini S, Fontas E, Ribeyron J, Metelkina-Fernandez V, Benoit M, Fernandez A, Askenazy F. Odyssee: protocol for a prospective cohort on psychiatric transition at age 17 in Nice, France. BMJ Open. 2026 Aug 25;16(8):e120667. doi: 10.1136/bmjopen-2026-120667.
PubMed 42642081
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Transition From Child Psychiatry to Adult Psychiatry in Nice Within a Population of 17-year-old Adolescents
- ClinicalTrials.gov ID
- NCT07068945
- Acronym / sponsor ID
- Odysee3 / 25-HPNCL-04 Odysee3
- Conditions
- Child Psychiatry
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Fondation LenvalUniversity, hospital or other
- Study start
- 7 Apr 2026 (actual)
- Primary completion
- 15 Sep 2028 (estimated)
- Study completion
- 15 Sep 2028 (estimated)
- First posted
- 16 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Transitional psychiatry addresses the complex process through which individuals move from adolescence to adulthood, both in terms of developmental stage and mental healthcare systems. This transition includes the shift from pediatric to adult psychiatric services, as well as the evolution from vague or subclinical symptoms to established psychiatric disorders that may become chronic without early intervention.
Psychiatric disorders often emerge early in life: approximately 50% before age 15 and 75% before age 25. Early detection and intervention are therefore crucial to improving long-term mental health outcomes, functional independence, and social integration. However, current healthcare systems frequently fail to meet the needs of adolescents and young adults during this critical transition phase. Organizational discontinuities and clinical complexity lead to several risks:
- Difficulties in accessing appropriate psychiatric care for adolescents presenting with emerging symptoms,
- High rates of service disengagement for patients already receiving pediatric mental health care who do not successfully transition to adult services.
Studies have shown that nearly half (48%) of young people drop out of psychiatric follow-up for at least three months after reaching adulthood. This interruption increases the likelihood of relapse and involuntary psychiatric admissions. Despite numerous publications over the past decade emphasizing the need for dedicated transitional care models, services remain fragmented in many systems.
One of the largest recent studies in this area, the European MILESTONE longitudinal study, followed 763 patients (mean age 17.5) over two years in eight countries. It found that 11% of participants discontinued care entirely, 41% experienced discontinuity, and only 21% successfully transitioned to adult psychiatry. Continued care was more likely among patients with severe psychiatric disorders who had already accepted treatment. In contrast, those with mood disorders or poorly defined symptoms-despite being at high risk-were less likely to receive ongoing support.
Transitional psychiatry therefore aims to establish integrated practices and systems that ensure the continuity of mental healthcare for youth aged approximately 16 to 25. The main objectives of such services are to:
- Prevent care disruptions at the age of majority,
- Maintain appropriate and developmentally sensitive treatment for young adults,
- Promote patient autonomy in managing their care,
- Ensure coordination and collaboration between child/adolescent and adult psychiatric teams.
Despite growing recognition of these needs, no consensus exists in the literature regarding a fixed duration that defines a true care discontinuity, and practices vary significantly between regions and systems.
In this context, the Odyssée 3 project was launched in Nice, France, as a prospective epidemiological study focusing specifically on the real-life transition from child and adolescent psychiatry to adult psychiatry. The study targets a cohort of 17-year-olds who are currently receiving mental health care and will soon face the shift to adult services.
The project is part of the CNR Santé Mentale territorial initiative, supported by the Regional Health Agency (ARS 06). It is co-led by the University Department of Child and Adolescent Psychiatry (SUPEA) at Lenval Pediatric University Hospital and the Department of Psychiatry at the Nice University Hospital (CHU de Nice).
Odyssey 3 has three primary goals:
- To assess the care pathways and clinical outcomes of adolescents undergoing transition to adult psychiatry;
- To identify patient profiles, trajectories, and risk factors associated with successful or failed care continuity;
- To generate data that will inform the creation of a dedicated transitional psychiatry team and pathway in the Nice area.
Ultimately, this study aims to strengthen the healthcare system's ability to detect early warning signs, intervene proactively in emerging psychiatric conditions, and ensure that adolescents already engaged in care do not experience service discontinuities. Its findings will serve as a foundation for building a specialized, coordinated, and sustainable transitional psychiatry structure in Nice, aligned with best practices and international recommendations.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Group of 17-year-old patients living in Nice and receiving psychiatric care | – | Behavioral: Group of 17-year-old patients living in Nice and receiving psychiatric careGroup of 17-year-old patients living in Nice and receiving psychiatric care |
Who may qualify
- Ages
- 17 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Group of 17-year-old patients living in Nice and receiving psychiatric care
Key inclusion criteria (7 listed)
- Age ≥17 and <18 years at inclusion.
- Receiving care (outpatient, inpatient, or emergency) within the Child and Adolescent Psychiatry Department at Lenval University Children's Hospital.
- Presence of a psychiatric disorder according to DSM-5 criteria, irrespective of diagnostic category.
- Considered to be in a potential transition situation to adult mental health services within the following 12 months.
- Living in the municipality of Nice (postal codes 06000, 06100, 06200, 06300).
Key exclusion criteria (7 listed)
- Insufficient command of French preventing comprehension of study information or completion of questionnaires.
- Cognitive or sensory impairments (e.g. moderate-to-severe intellectual disability, major visual impairment, severe reading difficulties) preventing valid completion of assessments.
- Legal incapacity (e.g. guardianship) preventing independent consent.
- Acute or unstable clinical condition requiring urgent or intensive care incompatible with research participation (e.g. severe psychiatric decompensation, immediate suicidal crisis).
- Refusal to participate by the adolescent or the parent(s)/legal representative(s).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group of 17-year-old patients living in Nice and receiving psychiatric careProspective study aiming to determine the annual prevalence of 17-year-old patients living in Nice who attend hospital-based child and adolescent psychiatry services. Secondary objectives include: estimating prevalence among under-18 psychiatric patients; describing clinical and sociodemographic profiles (sample of 100 patients); mapping 1-year care trajectories; evaluating clinical outcomes; assessing transition preparedness (to adult psychiatry); and identifying factors associated with psychiatric care continuity at 12 months. | Behavioural | Group of 17-year-old patients living in Nice and receiving psychiatric care |
Primary outcome
Annual prevalence of 17-year-old patients living in Nice who consulted hospital-based child and adolescent psychiatry services, calculated against the total number of 17-year-olds in the general population of Nice.
Time frame: one year
Annual prevalence is defined as the number of 17-year-old patients living in the city of Nice who consult hospital-based child and adolescent psychiatry services within a one-year period, divided by the total number of 17-year-olds in the general population of Nice. The calculation was performed using data from INSEE (French National Institute of Statistics and Economic Studies).
9 secondary outcomes
Annual Prevalence of 17-Year-Old Adolescents Consulting Child and Adolescent Psychiatric Services in Nice
Time frame: One year following the first psychiatric consultation during the study period.
Baseline Description of Patient Profiles in a Child and Adolescent Psychiatric Population
Time frame: Baseline
One-Year Psychiatric Care Trajectories in Adolescents
Time frame: 12 months after study inclusion
Clinical Evolution
Time frame: Baseline (M0), 6 months (M6), and 12 months (M12).
Transition Readiness and Appropriateness Measure (TRAM)
Time frame: Baseline (M0) and 6 months (M6).
Continuity of Psychiatric Care at 12 Months
Time frame: 12 months (M12).
WHOQOL-BREF Quality of Life Score
Time frame: Baseline (M0), 6 months (M6), and 12 months (M12).
Psychosocial Functioning (Health of the Nation Outcome Scales for Children and Adolescents [HoNOSCA] Total Score
Time frame: Baseline (M0), 6 months (M6), and 12 months (M12).
Outcome of Transition to Adult Psychiatric Care (Transition Related Outcome Measure [TROM] Total Score)
Time frame: 12 months (M12).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- Derived from this study: PubMed 42642081Dumas LE, Marchini S, Fontas E, Ribeyron J, Metelkina-Fernandez V, Benoit M, Fernandez A, Askenazy F. Odyssee: protocol for a prospective cohort on psychiatric transition at age 17 in Nice, France. BMJ Open. 2026 Aug 25;16(8):e120667. doi: 10.1136/bmjopen-2026-120667.
- Individual participant dataSharing planned: Yes. Deidentified individual participant data collected during the study will be made available upon reasonable request following publication of the primary results, subject to applicable ethical and legal regulations.
Related trials for Child Psychiatry
RecruitingPhase 1
Cannabidiol (CBD) in Adults With ASD
Autism Spectrum Disorder
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
RecruitingPhase 2
Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety
Psychiatric Disorders, Anxiety Disorders
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
Recruiting
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Louis-Emilie Dumas, Child and adolescent psychiatr contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Child Psychiatry, run by Fondation Lenval at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact ALINE JOULIE (+33492030520, joulie.a@chu-nice.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Annual prevalence of 17-year-old patients living in Nice who consulted hospital-based child and adolescent psychiatry services, calculated against the total number of 17-year-olds in the general population of Nice. (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07068945, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.